HT
GPCR icon

Headlands Technologies’s Structure Therapeutics GPCR Stock Holding History

Headlands Technologies’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,156
Closed -$1.79M – 823
2026
Q1 		$1.79M Sell
37,156
-6,573
-15% -$450K 0.2% 108
2025
Q4 		$3.04M Buy
43,729
+16,915
+63% +$691K 0.25% 76
2025
Q3 		$751K Buy
26,814
+4,476
+20% +$89.1K 0.06% 285
2025
Q2 		$463K Buy
22,338
+18,930
+555% +$416K 0.06% 314
2025
Q1 		$59K Sell
3,408
-752
-18% -$18.4K 0.01% 677
2024
Q4 		$113K Buy
+4,160
New +$148K 0.01% 641

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Headlands Technologies's GPCR Position: Q2 2026 in Review

Headlands Technologies sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 37,156 shares — an estimated $1.79M sold.

Headlands Technologies first reported a position in GPCR in Q4 2024 and held it in 6 quarters. The position peaked at $3.04M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Headlands Technologies reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 37,156 Structure Therapeutics shares in Q2 2026, an estimated $1.79M.
  • Headlands Technologies first reported a position in Structure Therapeutics in Q4 2024 and held it in 6 quarters.
  • Headlands Technologies's Structure Therapeutics position peaked at $3.04M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.